Candriam SCA’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.34M | Sell |
33,256
-1,366
| -4% | -$378K | 0.03% | 331 |
|
|
2026
Q1 | $10.2M | Sell |
34,622
-322
| -0.9% | -$95.6K | 0.05% | 279 |
|
|
2025
Q4 | $9.54M | Sell |
34,944
-46,650
| -57% | -$12.7M | 0.05% | 277 |
|
|
2025
Q3 | $22M | Sell |
81,594
-50,987
| -38% | -$13.9M | 0.12% | 171 |
|
|
2025
Q2 | $36.5M | Buy |
132,581
+49,537
| +60% | +$13.5M | 0.21% | 100 |
|
|
2025
Q1 | $22M | Buy |
83,044
+14,160
| +21% | +$3.49M | 0.14% | 149 |
|
|
2024
Q4 | $16M | Buy |
68,884
+42,413
| +160% | +$9.75M | 0.09% | 195 |
|
|
2024
Q3 | $5.84M | Sell |
26,471
-19,668
| -43% | -$4.07M | 0.03% | 339 |
|
|
2024
Q2 | $9.07M | Sell |
46,139
-53,469
| -54% | -$11M | 0.06% | 268 |
|
|
2024
Q1 | $21.4M | Sell |
99,608
-18,744
| -16% | -$3.94M | 0.14% | 156 |
|
|
2023
Q4 | $24.9M | Buy |
118,352
+92,918
| +365% | +$19.8M | 0.17% | 130 |
|
|
2023
Q3 | $5.09M | Sell |
25,434
-1,188
| -4% | -$236K | 0.04% | 308 |
|
|
2023
Q2 | $4.93M | Sell |
26,622
-2,166
| -8% | -$400K | 0.04% | 333 |
|
|
2023
Q1 | $5.07M | Buy |
28,788
+1,208
| +4% | +$218K | 0.04% | 359 |
|
|
2022
Q4 | $4.64M | Buy |
27,580
+2,511
| +10% | +$436K | 0.03% | 395 |
|
|
2022
Q3 | $4.44M | Sell |
25,069
-565
| -2% | -$112K | 0.03% | 407 |
|
|
2022
Q2 | $6.18M | Buy |
25,634
+404
| +2% | +$85.6K | 0.05% | 294 |
|
|
2022
Q1 | $6M | Buy |
25,230
+2,181
| +9% | +$512K | 0.04% | 317 |
|
|
2021
Q4 | $5.27M | Sell |
23,049
-1,782
| -7% | -$392K | 0.03% | 359 |
|
|
2021
Q3 | $4.8M | Buy |
24,831
+553
| +2% | +$112K | 0.03% | 405 |
|
|
2021
Q2 | $5.16M | Sell |
24,278
-144
| -0.6% | -$30.4K | 0.04% | 402 |
|
|
2021
Q1 | $4.27M | Hold |
24,422
| – | – | 0.04% | 402 |
|
|
2020
Q4 | $4.45M | Buy |
24,422
+1,992
| +9% | +$339K | 0.04% | 412 |
|
|
2020
Q3 | $3.75M | Sell |
22,430
-1,640
| -7% | -$276K | 0.04% | 394 |
|
|
2020
Q2 | $3.91M | Sell |
24,070
-6,994
| -23% | -$1.25M | 0.04% | 382 |
|
|
2020
Q1 | $6.09M | Hold |
31,064
| – | – | 0.07% | 300 |
|
|
2019
Q4 | $6.24M | Buy |
31,064
+1,898
| +7% | +$389K | 0.07% | 306 |
|
|
2019
Q3 | $6.16M | Buy |
29,166
+2,452
| +9% | +$512K | 0.08% | 274 |
|
|
2019
Q2 | $6.21M | Sell |
26,714
-3,026
| -10% | -$558K | 0.08% | 282 |
|
|
2019
Q1 | $4.89M | Buy |
29,740
+739
| +3% | +$131K | 0.06% | 332 |
|
|
2018
Q4 | $5.46M | Sell |
29,001
-213
| -0.7% | -$39.3K | 0.08% | 267 |
|
|
2018
Q3 | $4.97M | Sell |
29,214
-2,066
| -7% | -$348K | 0.07% | 316 |
|
|
2018
Q2 | $5.13M | Buy |
31,280
+3,262
| +12% | +$533K | 0.08% | 295 |
|
|
2018
Q1 | $4.53M | Buy |
28,018
+2,908
| +12% | +$463K | 0.08% | 299 |
|
|
2017
Q4 | $3.67M | Buy |
25,110
+1,393
| +6% | +$198K | 0.06% | 329 |
|
|
2017
Q3 | $3.22M | Buy |
23,717
+1,107
| +5% | +$140K | 0.06% | 360 |
|
|
2017
Q2 | $2.83M | Sell |
22,610
-908
| -4% | -$109K | 0.05% | 391 |
|
|
2017
Q1 | $2.79M | Buy |
23,518
+5,029
| +27% | +$605K | 0.05% | 375 |
|
|
2016
Q4 | $2.13M | Buy |
18,489
+1,209
| +7% | +$135K | 0.05% | 359 |
|
|
2016
Q3 | $1.81M | Buy |
17,280
+5,230
| +43% | +$546K | 0.04% | 376 |
|
|
2016
Q2 | $1.17M | Buy |
12,050
+2,598
| +27% | +$246K | 0.03% | 405 |
|
|
2016
Q1 | $903K | Sell |
9,452
-2,769
| -23% | -$252K | 0.02% | 447 |
|
|
2015
Q4 | $1.11M | Buy |
12,221
+5,542
| +83% | +$522K | 0.03% | 375 |
|
|
2015
Q3 | $619K | Sell |
6,679
-2,690
| -29% | -$256K | 0.02% | 496 |
|
|
2015
Q2 | $872K | Sell |
9,369
-62,507
| -87% | -$5.83M | 0.02% | 469 |
|
|
2015
Q1 | $6.81M | Buy |
71,876
+63,588
| +767% | +$5.89M | 0.14% | 198 |
|
|
2014
Q4 | $735K | Buy |
+8,288
| New | +$702K | 0.02% | 469 |
|
Other funds holding CME
Candriam SCA's CME Position: Q2 2026 in Review
Candriam SCA reduced its CME Group (CME) stake by 3.9% in Q2 2026, selling an estimated $378K and leaving 33,256 shares worth $7.34M. The position accounts for 0.03% of the portfolio, ranked #331.
Candriam SCA first reported a position in CME in Q4 2014 and has held it in 47 quarters since. The position peaked at $36.5M in Q2 2025. 1,701 funds tracked by Wall St. Rank hold CME as of Q2 2026.
- Candriam SCA held 33,256 shares of CME Group worth $7.34M as of Q2 2026.
- Candriam SCA sold 1,366 CME Group shares in Q2 2026, an estimated $378K.
- CME Group made up 0.03% of Candriam SCA's portfolio in Q2 2026, its #331 holding.
- Candriam SCA first reported a position in CME Group in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's CME Group position peaked at $36.5M in Q2 2025.
- 1,701 funds tracked by Wall St. Rank held CME Group as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.